Fengcai Zhu to Vaccination
This is a "connection" page, showing publications Fengcai Zhu has written about Vaccination.
Connection Strength
0.145
-
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021 02; 21(2):181-192.
Score: 0.036
-
Efficacy, immunogenicity and safety of the AS04-HPV-16/18 vaccine in Chinese women aged 18-25 years: End-of-study results from a phase II/III, randomised, controlled trial. Cancer Med. 2019 10; 8(14):6195-6211.
Score: 0.032
-
Effectiveness and practical uses of 23-valent pneumococcal polysaccharide vaccine in healthy and special populations. Hum Vaccin Immunother. 2018 04 03; 14(4):1003-1012.
Score: 0.029
-
Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Glob Health. 2017 03; 5(3):e324-e334.
Score: 0.027
-
The maternal viral threshold for antiviral prophylaxis of perinatal hepatitis B virus transmission in settings with limited resources: A large prospective cohort study in China. Vaccine. 2017 12 04; 35(48 Pt B):6627-6633.
Score: 0.007
-
Hemagglutinin-specific CD4+ T-cell responses following 2009-pH1N1 inactivated split-vaccine inoculation in humans. Vaccine. 2017 10 09; 35(42):5644-5652.
Score: 0.007
-
A phase 1 randomized open-label clinical study to evaluate the safety and tolerability of a novel recombinant hepatitis E vaccine. Vaccine. 2017 09 05; 35(37):5073-5080.
Score: 0.007